Dr. Motzer reviews the efficacy and safety data from the KEYNOTE-427 trial.
ENVISION Trial of UGN-102 Shows Durable Responses in LG-IR-NMIBC
February 3rd 2025Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Read More
Beckermann and Participants Discuss Second-Line ccRCC Options
January 22nd 2025During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.
Read More